Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / salesforce stock tumbled but many analysts maintain mwn benzinga


TECH - Salesforce Stock Tumbled But Many Analysts Maintain Long Term Optimism Despite Q1 Setback Eye AI Growth | Benzinga

Salesforce Inc (NYSE:CRM) shares are trading lower Thursday after multiple analysts slashed their price targets following the first-quarter print.

Salesforce reported first-quarter revenue of $9.13 billion, missing the analyst consensus of $9.15 billion. The adjusted EPS of $2.44 beat the analyst consensus of $2.38.

BofA Securities analyst Brad Sills reiterated a Buy rating and cut his price target from $360 to $288 on the demand environment reversion.

The analyst attributed the performance to the quarter’s weakening buying environment that the application companies faced after the short-lived fourth-quarter strength.

He acknowledged limited visibility on an improving software spending environment, casting doubt on second-quarter growth prospects.

Stifel analyst J. Parker Lane maintained a Buy with a price target of $300, down from $350.

Lane said various headwinds outweighed green shoots in Data Cloud, Industry Cloud, public sector, and financial services this quarter as the company noted a demand environment similar to the past two years.

While the macro’s current effect on the group is undoubted, the analyst continues to see Salesforce as a clear generative AI beneficiary over the coming years.

Truist Securities analyst Terry Tillman reiterated a Buy with a price target of $300, down from $360.

Salesforce had a mixed quarter. The company noted a continuation of measured buying behavior leading to longer deal cycles and deal compression but reiterated that it is seeing favorable trends with key growth levers like Data Cloud, multi-cloud adoption, and the Industry Clouds.

Tillman recommends buying on weakness as the profit improvement and capital allocation story is firmly intact.

The analyst added that Data Cloud, Industry Solutions, MuleSoft, and AI drivers could help subscription revenue and cRPO growth inflect going forward, especially in the seasonally stronger second half and amid any improved macro backdrop.

BMO Capital analyst Keith Bachman remained Outperform with a price target of $265, down from $335.

The quarter was disappointing, and the lowered revenue guidance left some risk, given the poor execution and buying environment witnessed in the first quarter.

Wedbush analyst Daniel Ives maintained an Outperform with a price target of $315, down from $325.

As per Ives, Salesforce is ...

Full story available on Benzinga.com

Stock Information

Company Name: Bio-Techne Corp
Stock Symbol: TECH
Market: NASDAQ
Website: bio-techne.com

Menu

TECH TECH Quote TECH Short TECH News TECH Articles TECH Message Board
Get TECH Alerts

News, Short Squeeze, Breakout and More Instantly...